The “Drug Smuggler” Scaring Big Pharma

[Details Enclosed] [Dow Drop Summit] March 12, 2023 [UNSUBSCRIBE]( Editor’s Note: At Dow Drop Summit we’re always looking out for special opportunities we believe you, as a valued subscriber, will want to see. Below you’ll find one from our partners at Behind the Markets. Please note that their opinions may differ from ours at Paradigm Press. The “Drug Smuggler” Scaring Big Pharma Dear Fellow Investor, They needed a "drug smuggler" to fight Alzheimer's All Big Pharma has on the market are drugs that treat the symptoms, not the disease itself. Drugs like Galantamine, which was discovered in the Soviet Union... in the 1950's! But now a small, publicly traded biotech is racing to the discovery of a lifetime: using a "drug smuggler" to Fight Alzheimer's, Parkinson's and Dementia. CNBC says this treatment "would help tens of millions of people." The Wall Street Journal says, "the financial benefits would be massive." That's enough to send shares of [this tiny biotech]( 10,000%. That's if Biogen, Sanofi and Genentech don't take them over first. They've paid over $1 billion for the rights to work with this "drug smuggler." [Get the stock symbol here ]( "The Buck Stops Here," [Dylan Jovine] [Paradigm]( © 2023 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Dow Drop Summit e-mail subscription and associated external offers sent from Dow Drop Summit, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Dow Drop Summit is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Dow Drop Summit subscription, you can ensure its arrival in your mailbox by [whitelisting Dow Drop Summit.](